This week in drug discovery (2-6 May)   

Swiss biotech sector sees strong performance in 2021, report says 

Switzerland’s life sciences sector saw a strong year in 2021 with companies contributing to the Covid-19 pandemic and high levels of capital investments being key indicators of the sector’s strength.   This is according to the latest edition of the Swiss Biotech Report which was launched by the Swiss Biotech Association.   

Promising results for Eli’s weight-loss drug   

Eli Lilly and Co’s potential weight-loss drug tirzepatide has shown positive results in a Phase III clinical trial, indicating at the therapy’s potential for patients with obesity and diabetes.   

Matica Biotechnology expands viral vector capacity 

Contract development and manufacturing organisation (CMDO) Matica Biotechnology has opened a new facility for the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.  

What an EMA decision means for data-based regulatory submissions 

The European Medicines Agency (EMA) has confirmed that the UNICOM’s DADI (Digital Application Dataset Integration) project will now serve as a ‘Plan B’ for the implementation of regulatory data submissions. Amplexor’s Renato Rjavec looks at the opportunities and challenges this presents for pharma companies. 

Amphista Therapeutics signs on drug development projects 

Amphista Therapeutics, a company focused on the development of next generation targeted protein degradation (TPD) therapeutics, has signed a strategic collaboration and license agreement with Bristol Myers Squibb.   

 

 

 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free